top of page

Search Results

Results found for "career development"

  • Activation of GPR183 by 7 α,25-Dihydroxycholesterol Induces Behavioral Hypersensitivity through...

    Nuclear Factor- κ B "Emerging evidence implicates the G-protein coupled receptor (GPCR) GPR183 in the development Further investigation of the signaling pathways downstream of GPR183 is needed to support the development intrathecal injection of its ligand, 7α,25-dihydroxycholesterol (7α,25-OHC), causes time-dependent development In support, we found that the development of 7α,25-OHC/GPR183-induced mechano-allodynia was associated

  • Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental...

    October 2022 Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental development Obesity, immunological diseases and endocrine metabolic diseases are high-risk factors for the development system function and the drug target exploration, we summarize the role of these receptors in placental development

  • 📰 GPCR Weekly News, April 1 to 7, 2024

    We're excited to share our coverage of the latest developments in GPCRs for this week. Hoare's workshop for individuals who live and work in developing countries. We define a developing country based on World Bank Classifications for its 2024 fiscal year. Dr.

  • 📰 GPCR Weekly News, October 23 to 29, 2023

    Propranolol with GPC-100 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for Exhibition June 2 - 7, 2024 | Chemotactic Cytokines GPCR Jobs NEW Staff Scientist (AC-TAP) in Database Development

  • GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors

    and clinical translation  — with tangible takeaways for programs from discovery through late-stage development Whether you’re in early discovery or clinical development, the strategies here could open doors in your

  • 📰 GPCR Weekly News, May 20 to 26, 2024

    differentiation through ERK activation GPCR Binders, Drugs, and more Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists Development of Putative Bivalent Dicovalent Ligands proteomics reveals CLR interactome in primary human cells Exploiting Cell-Based Assays to Accelerate Drug Development

  • G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease..

    ligands, which preferentially activate G protein or β-arrestin signaling pathways, are leading to the development and astrocytic hypertrophy, which suggest a protective glial response that may limit amyloid plaque development and β-arrestin signaling produce discrete and separable effects and provide proof of concept for the development

  • Canonical chemokine receptors as scavenging “decoys”

    direct cell migration during immune surveillance and inflammation, as well as to play vital roles in the development , maturation, and homing of lymphocytes and the development of organs.

  • Single-molecule counting applied to the study of GPCR oligomerization

    proteins that participate in many vital physiological functions making them a popular target for drug development Here, we review recent developments in single-molecule counting with a focus on photobleaching step counting

  • Molecular basis for ligand modulation of the cannabinoid CB 1 receptor

    A variety of ligands for CB1 receptors have been developed as promising drug candidates for the treatment These advances have paved the way for development of novel ligands for different therapeutic applications

  • New Podcast, Sweet Structures & $2.2B GPCR Moves

    membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop

  • Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

    Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance, to develop March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    The integration of AI in GPCR drug discovery has the potential to accelerate the identification and development Structure: the development of algorithms such DeepMind’s Alphafold2 (Jumper et al., 2021) and RoseTTAFold Open-source data: accessibility of databases to a wider audience will encourage the development of new Efforts will likely be made to develop AI models that can provide transparent explanations for their Precision medicines for GPCRs: AI can facilitate the development of personalized treatments by analyzing

  • 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024

    Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing 2 -3, 2024 Come and join top scientists in exploring the latest breakthroughs in GPCR-targeted drug development

  • Integrative model of the FSH receptor reveals the structural role of the flexible hinge region

    FSHR is involved in reproductive processes such as gonadal development and maturation. The models are expected to allow for testable hypotheses about signal transduction and drug development

  • Allosteric modulation of GPCRs: From structural insights to in silico drug discovery

    While traditional drug discovery programs have focused on the development of ligands targeting the binding with the plethora of GPCR structures available today, will facilitate structure-based discovery and development

  • Fluorescent Ligands Targeting Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2

    Here, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric By means of these studies, we developed 14 as a fluorescent CCR2 ligand, enabling cell-free as well as

  • Targeting Intracellular Allosteric Sites in GPCRs

    For this reason, GPCRs have been a focus of drug development for decades due to their role in regulating but recent breakthroughs in understanding allosteric modulation have opened up new avenues for drug development mechanisms Allosteric sites can differentially modulate G-protein and β-arrestin coupling, enabling the development biased signaling induced by intracellular allosteric agonists and establish a strong foundation for developing

  • Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game

    By iteratively refining the models with docking and mutagenesis data, they developed predictive pipelines

  • Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024

    biotechs hacking the cell signaling pathway From Structure to Solution: How Structural Biology Informs the Development Board GLP-1s like Ozempic are among the most important drug breakthroughs ever Goldman-backed drug developer

  • Domain Therapeutics Raises $42m Series A Financing

    May 2022 "Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development

  • High hedgehog signaling is transduced by a multikinase-dependent switch controlling the...

    October 2022 High hedgehog signaling is transduced by a multikinase-dependent switch controlling the apico-basal distribution of the GPCR smoothened "The oncogenic G-protein-coupled receptor (GPCR) Smoothened (SMO) is a key transducer of the hedgehog (HH) morphogen, which plays an essential role in the patterning of epithelial structures. Here, we examine how HH controls SMO subcellular localization and activity in a polarized epithelium using the Drosophila wing imaginal disc as a model. We provide evidence that HH promotes the stabilization of SMO by switching its fate after endocytosis toward recycling. This effect involves the sequential and additive action of protein kinase A, casein kinase I, and the Fused (FU) kinase. Moreover, in the presence of very high levels of HH, the second effect of FU leads to the local enrichment of SMO in the most basal domain of the cell membrane. Together, these results link the morphogenetic effects of HH to the apico-basal distribution of SMO and provide a novel mechanism for the regulation of a GPCR." Read more at the source #DrGPCR #GPCR #IndustryNews

  • TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms

    TRPM3 expression patterns differ between species and change during development. The aim of this review is to highlight recent results and developments with particular focus on findings

  • In vivo detection of GPCR-dependent signaling using fiber photometry and FRET-based biosensors

    biosensors are based on the principle of Förster resonance energy transfer (FRET), and we have recently developed neuroscience research, ranging from the study of neural circuits and behavior, to preclinical drug development

  • 📰 GPCR Weekly News, January 1 to 7, 2024

    Adhesion GPCRs The adhesion G-protein-coupled receptor mayo/CG11318 controls midgut development in Drosophila Structure, ligands, and roles of GPR126/ADGRG6 in the development and diseases GPCR Activation and Signaling electrostatic interactions Industry News Domain Therapeutics strengthens leadership team to spearhead global development

  • 📰 GPCR Weekly News, June 17 to 23, 2024

    Stay informed about the most recent developments in GPCR research and industry updates. of phytosterols and triterpenes isolated from Cryptostegia grandiflora against Candida auris FKBP12 Development and reprograms fungal cells for nematode hunting Role and recent progress of P2Y12 receptor in cancer development

  • ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the...

    Adhesion G Protein-Coupled Receptor L3 (ADGRL3) gene are associated with increased susceptibility to developing these in silico predictions of the ADGRL3-GIP interaction and dissect the complexity underlying the development

  • Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024

    Exclusive Deal for Scientists Residing and Working in Developing Nations If you live and work  in a developing This technique for studying cell receptors could have sweeping implications for drug development DeepCure of Neurological Disease s Activation of GPR55 alleviates neuropathic pain and chronic inflammation Developmental

  • Unlocking the Therapeutic Potential of Previously Undruggable GPCRs

    GPCR-targeting nanobodies. · Septerna: closed a $100 Million USD Series A round to develop small difficult-to-drug GPCRs. · Domain Therapeutics: completed a $42 Million USD Series A round to develop Developing Small Protein Therapeutics with a Novel Discovery Platform One way to overcome the challenges Orion used its discovery platform technology to rapidly develop a murinized version of OB-004 that was Relevant Publications Development of Orion’s platform technology Hartley, O. et al. (2004) Proceedings

  • Pharmacological Properties and Function of PxOctβ3 Octopamine Receptor in Plutella xylostella (L.)

    cruciferous vegetables, and insights into regulation of its physiological processes contribute towards the development the Octβ3 protein family, and an analysis using quantitative PCR showed that it was expressed at all developmental The injection of double-stranded RNA in an RNA interference assay indicated that PxOctβ3 regulates development

bottom of page